These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 31368016)
1. ASO Author Reflections: Clinical Implications of Programmed Death-Ligand 2 (PD-L2) Expression as an Independent Prognostic Marker in Lung Adenocarcinoma: Different Characteristics of PD-L2-Positive Patients from Those with Programmed Death-Ligand 1. Takamori S; Takada K; Maehara Y Ann Surg Oncol; 2019 Dec; 26(Suppl 3):668-669. PubMed ID: 31368016 [No Abstract] [Full Text] [Related]
2. ASO Author Reflections: PD-L2 Expression in Lung Squamous Cell Carcinoma-One of the Potential Important Prognostic Factors. Matsubara T; Takada K; Maehara Y Ann Surg Oncol; 2019 Dec; 26(Suppl 3):676-677. PubMed ID: 31385129 [No Abstract] [Full Text] [Related]
3. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745 [TBL] [Abstract][Full Text] [Related]
4. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893 [TBL] [Abstract][Full Text] [Related]
5. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803 [TBL] [Abstract][Full Text] [Related]
6. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. Zhou F; Wang X; Liu F; Meng Q; Yu Y Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. Hirai A; Yoneda K; Shimajiri S; Kuroda K; Hanagiri T; Fujino Y; Tanaka F J Thorac Cardiovasc Surg; 2018 Jan; 155(1):382-392.e1. PubMed ID: 28711324 [TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma. Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801 [TBL] [Abstract][Full Text] [Related]
11. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840 [TBL] [Abstract][Full Text] [Related]
12. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834 [TBL] [Abstract][Full Text] [Related]
13. High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma. Ding X; Zhang J; Shi M; Liu D; Zhang L; Zhang R; Su B; Ai K Clin Transl Oncol; 2021 Jan; 23(1):35-42. PubMed ID: 32472456 [TBL] [Abstract][Full Text] [Related]
14. Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy. Sotelo MJ; Cabezas-Camarero S; Riquelme A; Bueno C J Cancer Res Ther; 2020; 16(4):941-945. PubMed ID: 32930148 [TBL] [Abstract][Full Text] [Related]
15. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293 [TBL] [Abstract][Full Text] [Related]
16. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031 [TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance. Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525 [TBL] [Abstract][Full Text] [Related]
20. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]